Fierce Biotech February 25, 2024
Max Bayer

Johnson & Johnson is closing a nearly 200,000 square-foot R&D outpost in Brisbane, California, less than 18 months after it opened, according to multiple sources familiar with the decision.

A J&J spokesperson confirmed the closure in a statement sent to Fierce Biotech Sunday evening, saying that the company “will continue to have a significant footprint in California” across its pharma and medtech units, plus the establishment of a “new California Innovation Center.”

Sources familiar with the matter told Fierce that the decision to close the San Francisco Bay Campus (SFBC) was relayed to staff on Thursday. The site recently hosted J&J’s Gene Therapy Summit on February 15.

“As the world’s largest and most diversified healthcare products company, we continually...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Biopharma M&A more than doubled in the first quarter compared to the year prior: report
23andMe: What If …
Bruker brokers $392M deal for frayed NanoString
Pharma Pulse 4/18/24: Is it Fair Certain Biotech Investors Get an Early Look? The Health and Healthcare of Millennials & more
Pharmacies Should Adopt Proactive Health, Wellness to Help Patients

Share This Article